6HKA

The solution structure of the micelle-associated FATC domain of the human protein kinase ataxia telangiectasia mutated (ATM)

SOLUTION NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	2D 1H-15N HSQC	100 mM sodium chloride, 50 mM TRIS, 150 mM [U-100% 2H] DPC, 0.5 mM [U-100% 15N] 15N-hATMfatc	95% H2O/5% D2O	100 mM	6.5	1 atm	298	Bruker AVANCE III 500
2	2D 1H-15N HSQC	100 mM sodium chloride, 50 mM TRIS, 150 mM [U-100% 2H] DPC, 0.4 mM [U-100% 13C; U-100% 15N] 13C-15N-hATMfatc	95% H2O/5% D2O	100 mM	6.5	1 atm	298	Bruker AVANCE III 900
3	2D 1H-13C HSQC aliphatic	100 mM sodium chloride, 50 mM TRIS, 150 mM [U-100% 2H] DPC, 0.4 mM [U-100% 13C; U-100% 15N] 13C-15N-hATMfatc	95% H2O/5% D2O	100 mM	6.5	1 atm	298	Bruker AVANCE III 900
4	2D 1H-13C HSQC aromatic	100 mM sodium chloride, 50 mM TRIS, 150 mM [U-100% 2H] DPC, 0.4 mM [U-100% 13C; U-100% 15N] 13C-15N-hATMfatc	95% H2O/5% D2O	100 mM	6.5	1 atm	298	Bruker AVANCE III 900
5	2D 1H-13C HSQC	100 mM sodium chloride, 50 mM TRIS, 150 mM [U-100% 2H] DPC, 0.4 mM [U-10% 13C] 13C-hATMfatc	95% H2O/5% D2O	100 mM	6.5	1 atm	298	Bruker AVANCE III 500
6	3D HNCA	100 mM sodium chloride, 50 mM TRIS, 150 mM [U-100% 2H] DPC, 0.4 mM [U-100% 13C; U-100% 15N] 13C-15N-hATMfatc	95% H2O/5% D2O	100 mM	6.5	1 atm	298	Bruker AVANCE III 600
7	3D HNCACB	100 mM sodium chloride, 50 mM TRIS, 150 mM [U-100% 2H] DPC, 0.4 mM [U-100% 13C; U-100% 15N] 13C-15N-hATMfatc	95% H2O/5% D2O	100 mM	6.5	1 atm	298	Bruker AVANCE III 500
8	3D HCCH-TOCSY	100 mM sodium chloride, 50 mM TRIS, 150 mM [U-100% 2H] DPC, 0.4 mM [U-100% 13C; U-100% 15N] 13C-15N-hATMfatc	95% H2O/5% D2O	100 mM	6.5	1 atm	298	Bruker AVANCE III 600
9	3D C(CO)NH	100 mM sodium chloride, 50 mM TRIS, 150 mM [U-100% 2H] DPC, 0.4 mM [U-100% 13C; U-100% 15N] 13C-15N-hATMfatc	95% H2O/5% D2O	100 mM	6.5	1 atm	298	Bruker AVANCE III 600
10	3D HNHA	100 mM sodium chloride, 50 mM TRIS, 150 mM [U-100% 2H] DPC, 0.4 mM [U-100% 13C; U-100% 15N] 13C-15N-hATMfatc	95% H2O/5% D2O	100 mM	6.5	1 atm	298	Bruker AVANCE III 500
11	3D HNHB	100 mM sodium chloride, 50 mM TRIS, 150 mM [U-100% 2H] DPC, 0.4 mM [U-100% 13C; U-100% 15N] 13C-15N-hATMfatc	95% H2O/5% D2O	100 mM	6.5	1 atm	298	Bruker AVANCE III 500
12	3D 1H-15N NOESY	100 mM sodium chloride, 50 mM TRIS, 150 mM [U-100% 2H] DPC, 0.4 mM [U-100% 13C; U-100% 15N] 13C-15N-hATMfatc	95% H2O/5% D2O	100 mM	6.5	1 atm	298	Bruker AVANCE III 500
13	3D 1H-13C NOESY aliphatic	100 mM sodium chloride, 50 mM TRIS, 150 mM [U-100% 2H] DPC, 0.4 mM [U-100% 13C; U-100% 15N] 13C-15N-hATMfatc	95% H2O/5% D2O	100 mM	6.5	1 atm	298	Bruker AVANCE III 900
14	3D 1H-13C NOESY aromatic	100 mM sodium chloride, 50 mM TRIS, 150 mM [U-100% 2H] DPC, 0.4 mM [U-100% 13C; U-100% 15N] 13C-15N-hATMfatc	95% H2O/5% D2O	100 mM	6.5	1 atm	298	Bruker AVANCE III 900
15	15N-T1	100 mM sodium chloride, 50 mM TRIS, 150 mM [U-100% 2H] DPC, 0.5 mM [U-100% 15N] 15N-hATMfatc	95% H2O/5% D2O	100 mM	6.5	1 atm	298	Bruker AVANCE III 500
16	15N-T2	100 mM sodium chloride, 50 mM TRIS, 150 mM [U-100% 2H] DPC, 0.5 mM [U-100% 15N] 15N-hATMfatc	95% H2O/5% D2O	100 mM	6.5	1 atm	298	Bruker AVANCE III 500
17	1H-15N NOE	100 mM sodium chloride, 50 mM TRIS, 150 mM [U-100% 2H] DPC, 0.5 mM [U-100% 15N] 15N-hATMfatc	95% H2O/5% D2O	100 mM	6.5	1 atm	298	Bruker AVANCE III 500

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Bruker	AVANCE III	500
2	Bruker	AVANCE III	600
3	Bruker	AVANCE III	900

NMR Refinement
Method	Details	Software
simulated annealing		Xplor-NIH

NMR Ensemble Information
Conformer Selection Criteria	structures with the lowest energy
Conformers Calculated Total Number	200
Conformers Submitted Total Number	20
Representative Model	1 (lowest energy)

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	chemical shift assignment	NMRView		Johnson, One Moon Scientific
2	processing	NMRPipe		Delaglio, Grzesiek, Vuister, Zhu, Pfeifer and Bax
3	processing	NMRDraw		Delaglio, Grzesiek, Vuister, Zhu, Pfeifer and Bax
4	structure calculation	Xplor-NIH		Schwieters, Kuszewski, Tjandra and Clore

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.